Top

Published in:

Open Access 01-12-2018 | Research Article

Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors

Authors: X. Merino-Casabiel, J. Aller, J. Arbizu, R. García-Figueiras, C. González, E. Grande, P. Jiménez-Fonseca, M. I. Sevilla, J. Capdevila

Published in: Clinical and Translational Oncology | Issue 12/2018

Abstract

Purpose

Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should differ from other kind of tumors.

Methods

To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting.

Results

Expert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated.

Available only for authorised users

Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18 (vii). https://doi.org/10.1016/j.ecl.2010.12.005.CrossRef

de Mestier L, Dromain C, d’Assignies G, Scoazec JY, Lassau N, Lebtahi R, et al. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer. 2014;21(3):R105–20. https://doi.org/10.1530/ERC-13-0365.CrossRefPubMed

Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol. 2013;201(4):811–24. https://doi.org/10.2214/AJR.12.10240.CrossRefPubMedPubMedCentral

Held-Warmkessel J, Schiech L. Responding to four gastrointestinal complications in cancer patients. Nursing. 2008;38(7):32–8. https://doi.org/10.1097/01.nurse.0000325340.92199.e9 (quiz 9).CrossRefPubMed

Vinik AI, Woltering EA, Warner RRP, Caplin M, O’Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–34. https://doi.org/10.1097/mpa.0b013e3181ebaffd.CrossRefPubMed

Sundin A, Wills M, Rockall A. Radiological imaging: computed tomography, magnetic resonance imaging and ultrasonography. Front Horm Res. 2015;44:58–72. https://doi.org/10.1159/000382056.CrossRefPubMed

McDermott S, O’Neill AC, Skehan SJ. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach. Clin Imaging. 2013;37(2):194–200. https://doi.org/10.1016/j.clinimag.2012.05.006.CrossRefPubMed

Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Muller M, et al. Staging of neuroendocrine tumours: comparison of (⁶⁸Ga)DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13:63–72. https://doi.org/10.1102/1470-7330.2013.0007.CrossRefPubMedPubMedCentral

Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, et al. ⁶⁸Ga-DOTATATE PET/CT, ^99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med. 2014;55(10):1598–604. https://doi.org/10.2967/jnumed.114.144543.CrossRefPubMed

10.

Moryoussef F, de Mestier L, Belkebir M, Deguelte-Lardiere S, Brixi H, Kianmanesh R, et al. Impact of liver and whole-body diffusion-weighted MRI for neuroendocrine tumors on patient management: a pilot study. Neuroendocrinology. 2017;104(3):264–72. https://doi.org/10.1159/000446369.CrossRefPubMed

11.

Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015;34(4):823–42. https://doi.org/10.1007/s10555-015-9598-5.CrossRefPubMedPubMedCentral

12.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364–72. https://doi.org/10.2967/jnumed.112.111724.CrossRefPubMed

13.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with ⁶⁸Ga-DOTA-conjugated peptides: ⁶⁸Ga-DOTA-TOC, ⁶⁸Ga-DOTA-NOC, ⁶⁸Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10. https://doi.org/10.1007/s00259-010-1512-3.CrossRefPubMed

14.

Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, et al. Safety and efficacy of ⁶⁸Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708–14. https://doi.org/10.2967/jnumed.115.163865.CrossRefPubMed

15.

Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [¹⁸F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16(1):255–65. https://doi.org/10.1677/ERC-08-0229.CrossRefPubMed

16.

Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Goke B, et al. Intraindividual comparison of ⁶⁸Ga-DOTA-TATE and ¹⁸F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36(5):765–70. https://doi.org/10.1007/s00259-008-1030-8.CrossRefPubMed

17.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTATATE (DOTA-DPhe¹, Tyr³-octreotate) and ¹⁸F-FDG. Cancer. 2008;112(11):2447–55. https://doi.org/10.1002/cncr.23469.CrossRefPubMed

18.

Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of ⁶⁸Ga-DOTA-TOC and ¹⁸F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 2016;43(9):1585–92. https://doi.org/10.1007/s00259-016-3328-2.CrossRefPubMedPubMedCentral

19.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588–96. https://doi.org/10.1200/JCO.2015.64.0987.CrossRefPubMed

20.

Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefPubMed

21.

Has Simsek D, Kuyumcu S, Turkmen C, Sanli Y, Aykan F, Unal S, et al. Can complementary ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014;55(11):1811–7. https://doi.org/10.2967/jnumed.114.142224.CrossRefPubMed

22.

Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–46. https://doi.org/10.1016/S1470-2045(15)00186-2.CrossRefPubMedPubMedCentral

23.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. ⁶⁸Ga-DOTA-Tyr³-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50(9):1427–34. https://doi.org/10.2967/jnumed.108.053421.CrossRefPubMed

24.

Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, et al. Total ¹⁸F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging. 2011;38(10):1854–61. https://doi.org/10.1007/s00259-011-1862-5.CrossRefPubMedPubMedCentral

25.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

26.

Ducreux M, Dahan L, Smith D, O’Toole D, Lepere C, Dromain C, et al. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)—a phase II non-randomised trial. Eur J Cancer. 2014;50(18):3098–106. https://doi.org/10.1016/j.ejca.2014.10.002.CrossRefPubMed

27.

Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol. 2012;7(2):127–33. https://doi.org/10.1007/s11523-012-0216-y.CrossRefPubMed

28.

Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, et al. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015;44(2):190–7. https://doi.org/10.1097/MPA.0000000000000255.CrossRefPubMedPubMedCentral

29.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612–22. https://doi.org/10.1158/1078-0432.CCR-08-2057.CrossRefPubMed

30.

Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology. 2009;90(2):227–33. https://doi.org/10.1159/000225952.CrossRefPubMed

Title: Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors
Authors: X. Merino-Casabiel
J. Aller
J. Arbizu
R. García-Figueiras
C. González
E. Grande
P. Jiménez-Fonseca
M. I. Sevilla
J. Capdevila
Publication date: 01-12-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 12/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1881-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Please log in to get access to this content

Other articles of this Issue 12/2018

Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

This is a call to oncologists for action

Management of patients with implanted cardiac devices during radiotherapy: results of a Spanish survey in radiation oncology departments

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

New physical approaches to treat cancer stem cells: a review

Choice of antiepileptic drugs affects the outcome in cancer patients with seizures

Keynote webinar | Spotlight on antibody–drug conjugates in cancer